WINNIPEG, MANITOBA--(Marketwire - September 24, 2008) - Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent with Mount Sinai Services ("MSS") which would allow MSS to acquire FDA regulated commercial products known as Analyte Specific Reagents ("ASRs") in order to develop in house clinical tests for Miraculins' growing pipeline of biomarkers. Under the agreement, Miraculins will also retain MSS to provide laboratory and testing services for future clinical trials and regulatory clearance or approval studies involving other products that Miraculins may seek to develop.
